Related Experiment Videos
Somatostatin analog: effects on hypergastrinemia and hypercalcitoninemia
Abstract:
A somatostatin analog (SMS 201-995) was used to treat symptomatic patients with a residual tumor burden of gastrinoma or medullary thyroid carcinoma and pathologic elevations of circulating marker peptides associated with these neuroendocrine tumors. Possible inhibitory effects of the analog on marker peptides, patients' symptoms, or tumor progression were studied in a dose-response protocol and during several months of self-injection of SMS 201-995. Both patients reported remarkable relief of secretory diarrhea and other symptoms, and serum gastrin was successfully suppressed by increasing doses of the analog. However, no effect was seen in reduction of hypercalcitoninemia. Morphologic imaging of residual tumor showed no progression of medullary thyroid carcinoma during treatment and, in the case of hepatic gastrinoma metastases, remarkable tumor regression was confirmed. No toxicity or glucose intolerance was experienced. Somatostatin analog shows promise for palliative management of endocrinologic symptoms due to neuroendocrine tumors, and an inhibitory effect can be measured in some but not all peptide markers. Further evidence of its negative trophic effect on tumor blood flow may suggest an antineoplastic potential, as well as palliative use of this new treatment.
Insights
A novel somatostatin analog effectively managed symptoms and reduced tumor size in patients with neuroendocrine tumors like gastrinoma. This treatment shows promise for palliative care, with some peptide markers showing inhibition.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Neuroendocrine tumors (NETs) like gastrinoma and medullary thyroid carcinoma can cause significant symptoms due to hormone overproduction.
- Managing symptomatic NETs with residual tumor burden often requires addressing both hormonal imbalances and tumor progression.
Observation:
- A somatostatin analog (SMS 201-995) was administered to patients with symptomatic gastrinoma or medullary thyroid carcinoma.
- Treatment involved a dose-response protocol and several months of self-injection, monitoring symptoms, peptide markers, and tumor progression.
Findings:
- Patients experienced significant relief from secretory diarrhea and other symptoms.
- Serum gastrin levels were suppressed, but hypercalcitoninemia was unaffected.
- Tumor imaging revealed no progression of medullary thyroid carcinoma and regression of hepatic gastrinoma metastases.
- No significant toxicity or glucose intolerance was observed.
Implications:
- Somatostatin analog (SMS 201-995) demonstrates potential for palliative management of symptoms associated with neuroendocrine tumors.
- The analog may have an inhibitory effect on certain peptide markers and a negative trophic effect on tumor blood flow, suggesting antineoplastic potential.
- Further research is warranted to explore the full therapeutic benefits and mechanisms of action for NETs.